Journal Of Clinical Oncology (jco) Podcast

This podcast will explore the feasibility of a nonoperative "wait and see" approach based on strict selection criteria in patients with locally advanced rectal cancer who achieve a complete clinical response after chemoradiation.

This podcast reviews the evidence that women testing negative for known familial BRCA1/2 mutations should adhere to current population breast cancer screening guidelines.

This Podcast provides observation and commentary on the JCO article "Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer".

Podcast to review the article "Occult Metastases in Length Nodes Predict Survival In Resectable Non-Small Cell Lung Cancer: Report of the ACOSOG Z40040 Trial" by Rusch et al.

The ATAC investigators collected comorbidity data on more than 9000 women and this article illustrates that it provides key information.

Rapid, dramatic shifts are ongoing in the population-level epidemiology of oropharynx cancer in the United States.

EGFR mutation is a predictive biomarker for maintenance erlotinib but its clinical application is limited. This podcast will explain why.

This podcast summarizes the incidence and long-term outcome of osteonecrosis in a large prospective study of children treated for acute lymphhoblastic leukemia with the dexamethasone-based Dutch Childhood Oncology Group-ALL 9 Protocol.

This podcast evaluates the context and reviews results of a randomized phase III trial comparing R-CHOP given at conventional 21 day intervals with R-CHOP given at 14 day intervals in patients with newly diagnosed follicular lymphoma.

This podcast reviews the randomized double-blind placebo-controlled trial reported by Boekhout et al. that evaluates venlafaxine and clonidine for the treatment of hot flashes in women with breast cancer.

This podcast reviews the retrospective study by Arun et al. and discusses the lack of consensus regarding the relative chemosensitivity of breast cancers in mutation carriers and non-carriers as well as the optimal neoadjuvant chemotherapy for mutation carriers.

Androgen deprivation therapy may not be associated with an increase in cardiovascular mortality in all men but only those with a prior cardiac event due to known coronary artery disease.

Stage II colon cancer with high risk factors is often treated with adjuvant therapy, however new data raise questions about the usefulness of this practice.

Commentary on a successful study in which genotype-guided tamoxifen dosing increased endoxifen concentrations in women with reduced CYP2D6 metabolism.

Estrogen plus progestin and estrogen alone have different effects on mammographic density and breast cancer.

This is a commentary on a recent study comparing two risk calculators for use in the setting of prostate cancer screening.

This podcast describes the analysis of the IPASS study population by EGFR mutation and EGFR FISH biomarker status, and also discusses the results and controversial analysis of overall survival from this trial.

The use of arsenic trioxide as a single agent can produce long lasting remissions and a significant cure rate in patients with acute promyelocytic leukemia.

In this podcast, results of randomized phase III clinical trial evaluating the effects of a patient specific idiotype tumor vaccine in patients with follicular lymphoma are summarized. The results demonstrate that idiotype vaccination may improve disease free survival in patients with follicular lymphoma who achieve a remission following chemotherapy.

The addition of oxaliplatin to fluorouracil-based neoadjvuant chemoradiation for locally advanced rectal cancer significantly increases toxicity but does not improve the pathologic complete response rate.